Seborrhea - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Seborrhea - Pipeline Review, H2 2016’, provides an overview of the Seborrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Seborrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seborrhea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape of Seborrhea
  
• The report reviews pipeline therapeutics for Seborrhea by companies and universities/research institutes based on information derived from company and industry-specific sources
  
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  
• The report reviews key players involved Seborrhea therapeutics and enlists all their major and minor projects
  
• The report assesses Seborrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  
• The report summarizes all the dormant and discontinued pipeline projects
  
• The report reviews latest news related to pipeline therapeutics for Seborrhea

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  
• Identify and understand important and diverse types of therapeutics under development for Seborrhea
  
• Identify potential new clients or partners in the target demographic
  
• Develop strategic initiatives by understanding the focus areas of leading companies
  
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  
• Devise corrective measures for pipeline projects by understanding Seborrhea pipeline depth and focus of Indication therapeutics
  
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Seborrhea Overview 6
Therapeutics Development 7
Pipeline Products for Seborrhea - Overview 7
Seborrhea - Therapeutics under Development by Companies 8
Seborrhea - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Seborrhea - Products under Development by Companies 12
Seborrhea - Companies Involved in Therapeutics Development 13
Aclaris Therapeutics Inc 13
Amorepacific Corporation 14
Biomar Microbial Technologies 15
EpiPharm AG 16
Phosphagenics Limited 17
Seborrhea - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 26
artemether - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
hydrogen peroxide - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
IB-07A081 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
IB-07A085 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
ketoconazole - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
PAC-14028 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Seborrhea - Dormant Projects 34
Seborrhea - Discontinued Products 35
Seborrhea - Product Development Milestones 36
Featured News & Press Releases 36
Jul 25, 2016: Aclaris Therapeutics Completes Enrollment of Phase 3 Pivotal Trials of A-101 for the Treatment of Seborrheic Keratosis; Provides Update on Clinical Programs 36
Jan 19, 2016: Aclaris Therapeutics Initiates Phase 3 Clinical Trials of A-101 for the Treatment of Seborrheic Keratosis 36
Mar 17, 2015: Aclaris Therapeutics’ Lead Drug Candidate A-101 Achieves Statistically Significant Results in Third Phase 2 Clinical Trial for Seborrheic Keratosis, a Common Type of Benign Skin Tumor 36
Jan 27, 2015: Aclaris Therapeutics Announces Positive Results from Phase 2b Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Benign Skin Tumor 37
Jun 30, 2014: Aclaris Therapeutics Announces Positive Results from Phase 2 Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Skin Tumor 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 39
Disclaimer 40

List of Tables

Number of Products under Development for Seborrhea, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Seborrhea - Pipeline by Aclaris Therapeutics Inc, H2 2016 13
Seborrhea - Pipeline by Amorepacific Corporation, H2 2016 14
Seborrhea - Pipeline by Biomar Microbial Technologies, H2 2016 15
Seborrhea - Pipeline by EpiPharm AG, H2 2016 16
Seborrhea - Pipeline by Phosphagenics Limited, H2 2016 17
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Stage and Target, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 25
Seborrhea - Dormant Projects, H2 2016 34
Seborrhea - Discontinued Products, H2 2016 35

List of Figures

Number of Products under Development for Seborrhea, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Targets, H2 2016 19
Number of Products by Stage and Targets, H2 2016 19
Number of Products by Mechanism of Actions, H2 2016 21
Number of Products by Stage and Mechanism of Actions, H2 2016 21
Number of Products by Routes of Administration, H2 2016 23
Number of Products by Stage and Routes of Administration, H2 2016 23
Number of Products by Stage and Molecule Types, H2 2016 25